Barinthus Biotherapeutics (NASDAQ:BRNS – Free Report) had its target price lowered by Barclays from $7.00 to $3.00 in a report issued on Thursday, Benzinga reports. Barclays currently has an overweight rating on the stock.
Separately, HC Wainwright restated a buy rating and issued a $8.00 target price on shares of Barinthus Biotherapeutics in a report on Friday, June 7th.
View Our Latest Research Report on BRNS
Barinthus Biotherapeutics Stock Performance
Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.64) by $0.24. On average, research analysts predict that Barinthus Biotherapeutics will post -2.3 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Barinthus Biotherapeutics
A hedge fund recently bought a new stake in Barinthus Biotherapeutics stock. DC Funds LP acquired a new stake in shares of Barinthus Biotherapeutics plc (NASDAQ:BRNS – Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 642,204 shares of the company’s stock, valued at approximately $1,528,000. Barinthus Biotherapeutics makes up 14.8% of DC Funds LP’s investment portfolio, making the stock its 3rd biggest position. DC Funds LP owned 1.65% of Barinthus Biotherapeutics as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 25.20% of the company’s stock.
Barinthus Biotherapeutics Company Profile
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.
See Also
- Five stocks we like better than Barinthus Biotherapeutics
- How to Choose Top Rated Stocks
- MarketBeat Week in Review – 6/10 – 6/14
- Investing in the High PE Growth Stocks
- Top 5 High-Performance Cryptocurrency ETFs to Watch
- What is the S&P 500 and How It is Distinct from Other Indexes
- 3 Stocks That Plummeted After the Post-Fed Speech Crash
Receive News & Ratings for Barinthus Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Barinthus Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.